Charles Lu, MD, SM
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1998 | Harvard School of Public Health, Boston, MA, USA, MS, Clinical Epidemiology |
| 1991 | Yale University School of Medicine, New Haven, CT, USA, MD, Medicine |
| 1986 | Harvard College, Cambridge, MA, USA, AB, Biochemical Sciences |
Postgraduate Training
| 1997-1999 | Research Fellowship, Cancer Epidemiology, Harvard School of Public Health, Boston, MA |
| 1994-1997 | Clinical Fellowship, Medical Oncology and Hematology, Brigham and Women′s Hospital, Boston, MA |
| 1992-1994 | Clinical Residency, Internal Medicine, Brigham and Women′s Hospital, Boston, MA |
| 1991-1992 | Clinical Internship, Internal Medicine, Brigham and Women′s Hospital, Boston, MA |
| 1991-1998 | Clinical Fellowship, Harvard Medical School, Boston, MA |
Board Certifications
| 1998 | American Board of Internal Medicine, Hematology |
| 1997 | American Board of Internal Medicine, Medical Oncology |
| 1994 | American Board of Internal Medicine, Internal Medicine |
Selected Publications
Peer-Reviewed Articles
- Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu, C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
- Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu, C, Nguyen QN, Liao Z. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol 16(2):269-277, 2021. e-Pub 2020. PMID: 33198942.
- Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu, C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
- Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu, C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 26(14):3525-3536, 2020. e-Pub 2020. PMID: 32193228.
- Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu, C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2019. PMID: 31778797.
- Gunn GB, Mendoza TR, Garden AS, Wang XS, Shi Q, Morrison WH, Frank SJ, Phan J, Fuller CD, Chambers MS, Hanna EY, Lu, C, Rosenthal DI, Cleeland CS. Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Support Care Cancer 28(1):261-269, 2020. e-Pub 2019. PMID: 31037378.
- Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu, C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 29(3):499-505, 2011. e-Pub 2010. PMID: 20094773.
- Lu, C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy With or Without AE-941 in Stage III Non-Small Cell Lung Cancer: A Randomized Phase III Trial. J. Natl. Cancer Inst 102(12):859-865, 2010. PMID: 20505152.
- Wang XS, Shi Q, Lu, C, Basch EM, Johnson VE, Mendoza TR, Mobley GM, Cleeland CS. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer 116(1):137-45, 2010. e-Pub 2009. PMID: 19852033.